From the 27th until the 30th of October 2024, the 16th International Oncolytic Virotherapy Conference (IOVC) took place in Rotterdam, the Netherlands. International researchers from academia and industry focusing on oncolytic viruses (OVs) gathered in this city of “dreamers and doers.” Extensive developments in the OV field from fundamental, pre-clinical, and clinical levels were discussed. Both the oral and poster sessions focused on scientific progress made in clinical trials, combination therapies, mechanisms of action, novel platforms and payloads, tumor microenvironment (TME), and for the first time, biomarkers of response.
No takes yet. Share an insight, caveat, or question.
Stavrakaki et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: